Start Over

Characterizing Metastatic HER2 -Positive Gastric Cancer at the CDH1 Haplotype.

Authors :: Caggiari L
Miolo G
Buonadonna A
Basile D
Santeufemia DA
Cossu A
Palmieri G
De Zorzi M
Fornasarig M
Alessandrini L
Canzonieri V
Lo Re G
Puglisi F
Steffan A
Cannizzaro R
De Re V
Source :: International journal of molecular sciences [Int J Mol Sci] 2017 Dec 23; Vol. 19 (1). Date of Electronic Publication: 2017 Dec 23.
Publication Year :: 2017
Abstract: The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 ( HER2 ) is amplified and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a fraction of patients. The aim of this study was to improve knowledge of the HER2 and the E-cadherin alterations in the context of GC to characterize subtypes of patients that could better benefit from targeted therapy. An association between the P7- CDH1 haplotype, including two polymorphisms (rs16260A-rs1801552T) and a subset of HER2 -positive mGC with better prognosis was observed. Results indicated the potential evaluation of CDH1 haplotypes in mGC to stratify patients that will benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding the HER2 and the E-cadherin interactions in vivo and in response to treatments.<br />Competing Interests: The authors declare no conflict of interest.